Stocks · News reference
Barclays analyst Andrew Mok maintains Encompass Health (NYSE:EHC) with a Overweight and raises the price target from $140 to $144.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Encompass Health (NYSE:EHC) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
- Sec Filing
Encompass Health's EVP and general counsel John Patrick Darby sold 8,906 shares (11% of his direct holdings) for $1.1 million on August 10, 2026, following strong earnings and a stock rally. The sale comes after the company raised guidance due to a favorable 2.3% Medicare rate increase for inpatient rehabilitation services starting in October. While multiple insiders trimmed positions after the earnings-driven rally, the article emphasizes that Medicare reimbursement rates are the key factor for investors to monitor, as they directly impact the company's pricing and profitability.
Encompass Health's CFO Douglas Coltharp sold 18,869 shares worth $2.4 million on August 10, reducing his direct stake by 27% but maintaining a total beneficial ownership of 241,000 shares valued at $30.4 million. The sale occurred the same day as the CEO's larger stake reduction, following strong Q2 earnings that included 10% revenue growth, raised full-year guidance, and increased dividend/buyback authorization.